Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > «Prescribe not prescribe»: the role of β-blockers in modern treatment of patients with arterial hypertension and concomitant disorders

«Prescribe not prescribe»: the role of β-blockers in modern treatment of patients with arterial hypertension and concomitant disorders

Sergey R. Gilyarevsky , Ksenia A. Eruslanova , Nana G. Bendeliani , Anna Yu. Shchedrina , Maria V. Golshmid , Olga N. Tkacheva

For citation:


  • Abstract
  • About the Author
  • References

Abstract

The paper is focused on clarifying the role of using β-blockers in modern treatment of arterial hypertension (AH) in patients with comorbidities. Despite the fact that the majority of clinical guidelines on the treatment tactics for AH consider β-blockers as the drugs prescribed when there are certain additional indications, nowadays an attempt is made to return to the distant past of cardiology, when β-blockers played a role of first line antihypertensive drugs. The paper provides evidence-based arguments in favor of the balanced approach to prescription of β-blockers to patients with AH. At the same time, the paper presents the results of the recent analysis involving the data on the participants of the large randomized trial focused on assessing the effects of dapagliflozin in patients with heart failure and preserved left ventricular ejection fraction suggesting frequent use of β-blockers in clinical practice for patients with AH and concomitant disorders, as well as the β-blockers’ safety and probable efficacy. The paper provides the meta-analysis results allowing one to estimate antihypertensive effect of β-blockers, the use of which makes it possible to reduce systolic blood pressure by almost 8—10 mm Hg. Furthermore, the paper discusses an opportunity to quickly obtain information about the role of certain drugs for treatment of AH using ChatGPT that is considered to be a promising information technology. The paper also provides data on the use of the doses of β-blockers that are not high enough and does not allow to achieve optimal heart rate in clinical practice.
Keywords: arterial hypertension, beta blockers, clinical guidelines, concomitant disorders.

About the Author

Sergey R. Gilyarevsky 1 , Ksenia A. Eruslanova 2 , Nana G. Bendeliani 3 , Anna Yu. Shchedrina 2 , Maria V. Golshmid 4 , Olga N. Tkacheva 2

1 Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia

2 Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University, Moscow, Russia

3 Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russia

4 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

References

1. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480
2. Mancia G, Brunström M, Burnier M et al. Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension 2024;81(5): 1021-30. DOI: 10.1161/HYPERTENSIONAHA.124.22821
3. Messerli FH, Bangalore S, Mandrola JM. β blockers switched to first-line therapy in hypertension. Lancet 2023;402(10414):1802-4. DOI: 10.1016/S0140-6736(23)01733–1736
4. Pickering GW. High blood pressure, 2nd edn. London: J & A Churchill, 1968.
5. Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3
6. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906. DOI: 10.1016/S0140-6736(05)67185-1
7. Kjeldsen SE, Dahlöf B, Devereux RB et al.; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288(12):1491-8. DOI: 10.1001/jama.288.12.1491
8. Wei J, Galaviz KI, Kowalski AJ et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2020;3(2):e1921618. DOI: 10.1001/jamanetworkopen.2019. 21618
9. Williams B, Mancia G, Spiering W et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021-104. DOI: 10.1093/eurheartj/ehy339
10. Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020;75(6):1334-57. DOI: 10.1161/HYPERTENSIONAHA.120.15026
11. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):1269-324. DOI: 10.1161/HYP.0000000000000066. Erratum in: Hypertension 2018;71(6):e136-e139. Erratum in: Hypertension 2018;72(3):e33.
12. Rabi DM, McBrien KA, Sapir-Pichhadze R et al. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol 2020;36(5):596-624. DOI: 10.1016/j.cjca.2020.02.086
13. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003
14. Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol 2019;14(5):757-64. DOI: 10.2215/CJN.04330418
15. Converse RL Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327(27):1912-8. DOI: 10.1056/NEJM199212313272704
16. Ziff OJ, Samra M, Howard JP et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 2020;18(1):103. DOI: 10.1186/s12916-020-01564-3
17. Peikert A, Bart BA, Vaduganathan M et al. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. JACC Heart Fail 2024;12(4):631-44. DOI: 10.1016/j.jchf.2023.09.007
18. Arnold SV, Silverman DN, Gosch K et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC Heart Fail 2023;11(8 Pt. 1):893-900. DOI: 10.1016/j.jchf.2023. 03.017
19. Silverman DN, Plante TB, Infeld M et al. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open 2019 2;2(12):e1916598. DOI: 10.1001/jamanetworkopen.2019.16598
20. Palau P, Seller J, Domínguez E et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol 2021;78(21):2042-56. DOI: 10.1016/j.jacc.2021. 08.073. Erratum in: J Am Coll Cardiol 2022;79(8):848.
21. Myhre PL, Vaduganathan M, Claggett BL et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol 2018;3(10):1000-5. DOI: 10.1001/jamacardio.2018.2568
22. Infeld M, Wahlberg K, Cicero J et al. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial. JAMA Cardiol 2023;8(3):213-21. DOI: 10.1001/jamacardio.2022.5320
23. Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 2016;3(3):CD007451. DOI: 10.1002/14651858. CD007451.pub2
24. Chen ZM, Pan HC, Chen YP et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366 (9497):1622-32. DOI: 10.1016/S0140-6736(05)67661-1
25. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7. DOI: 10.1016/S0140-6736(99) 04440-2
26. Kendall MJ. Metoprolol-controlled release, zero order kinetics. J Clin Pharm Ther 1989;14(3):159-79. DOI: 10.1111/j.1365-2710.1989. tb00235.x
27. Dave T, Athaluri SA, Singh S. ChatGPT in medicine: an overview of its applications, advantages, limitations, future prospects, and ethical considerations. Front Artif Intell 2023;6:1169595. DOI: 10.3389/frai. 2023.1169595
28. Kharat A. (2022). Artificial Intelligence And Its Role In Healthcare. Available online at: https://www.entrepreneur.com/en-in/technology/artificial-intelligence-and-its-role-in-healthcare/427963healthcare (accessed March 7, 2023).
29. Huang J, Tan M. The role of ChatGPT in scientific communication: writing better scientific review articles. Am J Cancer Res 2023;13(4):
1148-54.
30. Gordijn B, Have HT. ChatGPT: evolution or revolution? Med Health Care Philos 2023;26(1):1-2. DOI: 10.1007/s11019-023-10136-0
31. van Dis EAM, Bollen J, Zuidema W et al. ChatGPT: five priorities for research. Nature 2023;614(7947):224-6. DOI: 10.1038/d41586-023-00288-7
32. Garg RK, Urs VL, Agarwal AA et al. Exploring the role of ChatGPT in patient care (diagnosis and treatment) and medical research: A systematic review. Health Promot Perspect 2023;13(3):183-91. DOI: 10.34172/hpp.2023.22

For citation:Gilyarevsky S.R., Yerulanova K.A., Bendeliani N.G., Shchedrina A.Yu., Golshmid M.V., Tkacheva O.N. «Prescribe not prescribe»: the role of β-blockers in modern treatment of patients with arterial hypertension and concomitant disorders. Clinical analysis in general medicine. 2024; 5 (2): 31–37 (In Russ.) DOI: 10.47407/kr2023.5.2.00385


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru